Literature DB >> 19423014

Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging.

Nele Evens1, Giulio G Muccioli, Nele Houbrechts, Didier M Lambert, Alfons M Verbruggen, Koen Van Laere, Guy M Bormans.   

Abstract

INTRODUCTION: The type 2 cannabinoid (CB(2)) receptor is part of the endocannabinoid system and has been suggested as a mediator of several central and peripheral inflammatory processes. Imaging of the CB(2) receptor has been unsuccessful so far. We synthesized and evaluated a carbon-11- and a fluorine-18-labeled 2-oxoquinoline derivative as new PET tracers with high specificity and affinity for the CB(2) receptor.
METHODS: Two 2-oxoquinoline derivatives were synthesized and radiolabeled with either carbon-11 or fluorine-18. Their affinity and selectivity for the human CB(2) receptor were determined. Biological evaluation was done by biodistribution, radiometabolite and autoradiography studies in mice.
RESULTS: In vitro studies showed that both compounds are high affinity CB(2)-specific inverse agonists. Biodistribution study of the tracers in mice showed a high in vivo initial brain uptake and fast brain washout, in accordance with the low CB(2) receptor expression levels in normal brain. A persistently high in vivo binding to the spleen was observed, which was inhibited by pretreatment with two structurally unrelated CB(2) selective inverse agonists. In vitro autoradiography studies with the radioligands confirmed CB(2)-specific binding to the mouse spleen.
CONCLUSION: We synthesized two novel CB(2) receptor PET tracers that show high affinity/selectivity for CB(2) receptors. Both tracers show favourable characteristics as radioligands for central and peripheral in vivo visualization of the CB(2) receptor and are promising candidates for primate and human CB(2) PET imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423014     DOI: 10.1016/j.nucmedbio.2009.01.009

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  20 in total

Review 1.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

2.  Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease.

Authors:  Rawaha Ahmad; Andrey Postnov; Guy Bormans; Jan Versijpt; Mathieu Vandenbulcke; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-03       Impact factor: 9.236

3.  Preclinical evaluation of [18 F]MA3: a CB2 receptor agonist radiotracer for PET.

Authors:  Bala Attili; Sofie Celen; Muneer Ahamed; Michel Koole; Chris Van Den Haute; Wim Vanduffel; Guy Bormans
Journal:  Br J Pharmacol       Date:  2019-01-30       Impact factor: 8.739

4.  Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model.

Authors:  Caroline Vandeputte; Cindy Casteels; Tom Struys; Michel Koole; Daisy van Veghel; Nele Evens; Anneleen Gerits; Tom Dresselaers; Ivo Lambrichts; Uwe Himmelreich; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-16       Impact factor: 9.236

5.  Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.

Authors:  Nashaat Turkman; Aleksander Shavrin; Roman A Ivanov; Brian Rabinovich; Andrei Volgin; Juri G Gelovani; Mian M Alauddin
Journal:  Bioorg Med Chem       Date:  2011-08-05       Impact factor: 3.641

6.  Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2).

Authors:  Andrew G Horti; Yongjun Gao; Hayden T Ravert; Paige Finley; Heather Valentine; Dean F Wong; Christopher J Endres; Alena V Savonenko; Robert F Dannals
Journal:  Bioorg Med Chem       Date:  2010-05-25       Impact factor: 3.641

7.  Synthesis and preliminary evaluation of [18F]-labeled 2-oxoquinoline derivatives for PET imaging of cannabinoid CB2 receptor.

Authors:  Nashaat Turkman; Aleksander Shavrin; Vincenzo Paolillo; Hsin Hsien Yeh; Leo Flores; Suren Soghomonian; Brian Rabinovich; Andrei Volgin; Juri Gelovani; Mian Alauddin
Journal:  Nucl Med Biol       Date:  2012-01-04       Impact factor: 2.408

8.  In vivo type 2 cannabinoid receptor-targeted tumor optical imaging using a near infrared fluorescent probe.

Authors:  Shaojuan Zhang; Pin Shao; Mingfeng Bai
Journal:  Bioconjug Chem       Date:  2013-10-29       Impact factor: 4.774

9.  Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects.

Authors:  Rawaha Ahmad; Michel Koole; Nele Evens; Kim Serdons; Alfons Verbruggen; Guy Bormans; Koen Van Laere
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

10.  Positron emission tomography (PET) imaging with (18)F-based radiotracers.

Authors:  Mian M Alauddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.